Author(s):
Perumal S, Langeswaran K
Email(s):
dr.langeswaran@gmail.com
DOI:
10.5958/0974-360X.2020.00308.X 
Address:
Perumal S1, Langeswaran K2*
1Department of Biochemistry, Vels Institute of Science and Technology and Advance Studies, Chennai, Tamil Nadu, India.
2Cancer Genetics and Molecular Biology Laboratory, Department of Bioinformatics, Science Campus, Alagappa University, Karaikudi, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 4,
Year - 2020
ABSTRACT:
The present study absorbed the anti-cancer activity of diosmin at 50, 100, 150, 200 µM/ml for 24h of treatment on dose dependent manner. Group II animals were administrated 0.01% NDEA to induce primary liver carcinoma. Cancer bearing experimental animals were treated orally with the drug diosmin at the dosage level of 200 mg per kg/bodyweight for 28 successive days. Results: Diosmin treatment on HepG2 cells constrains nearly half of the cell population and proliferation at the dose of 100 µM/ml and in vivo experimental studies showed remarkable repossession in biochemical and morphological characteristics. These results summarizes that both in vivo and in vitro anti-carcinogenic activity of diosmin could be an outstanding flavonoid in the treatment of HCC because of its therapeutic and pharmacological properties.
Cite this article:
Perumal S, Langeswaran K. Diosmin anti-tumour efficacious against Hepatocellular Carcinoma. Research J. Pharm. and Tech. 2020; 13(4):1707-1714. doi: 10.5958/0974-360X.2020.00308.X
Cite(Electronic):
Perumal S, Langeswaran K. Diosmin anti-tumour efficacious against Hepatocellular Carcinoma. Research J. Pharm. and Tech. 2020; 13(4):1707-1714. doi: 10.5958/0974-360X.2020.00308.X Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-4-18
REFERENCES:
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016.CA Cancer J Clin 2016; 66(1): 7-30.
2. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol 2015; 9(6): 765-79.
3. George VC, Dellaire G, Rupasinghe HPV. Plant flavonoids in cancer chemoprevention: role in genome stability.J NutrBiochem 2017; 45: 1-14.
4. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumor activities of flavonoids.In Vivo 2005; 19(5): 895-909.
5. Soobrattee MA, Neergheen VS, Luximon-Ramma A, Aruoma OI, Bahorun T. Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat Res 2005; 579(1-2): 200-13.
6. Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev 2012; 13(2):427-36.
7. Eraslan G, Sarıca ZS, Bayram LÇ, Tekeli MY, Kanbur M, Karabacak M. The effects of diosmin on aflatoxin-induced liver and kidney damage. Environ Sci Pollut Res Int 2017; 24(36): 27931-27941.
8. Naso L, Martínez VR, Lezama L, Salado C, Valcarcel M, Ferrer EG, et al. Antioxidant, anticancer activities and mechanistic studies of the flavone glycoside diosmin and its oxidovanadium (IV) complex. Interactions with bovine serum albumin. Bioorg Med Chem 2016; 24(18): 4108-4119.
9. Yuan J, Wu XJ, Lu WQ, Cheng XL, Chen D, Li XY, et al.Merschsundermann V. Chlorinated river and lake water extract caused oxidative damage, DNA migration and cytotoxicity in human cells. International Journal of Hygiene and Environmental Health2005; 208(6): 481-488.
10. King J. The Transferases-alanine and aspartate transaminases. In: Practical and Clinical Enzymology, (Eds.) by Van Nostrand Co.Ltd., London;1965a.p. 121-138.
11. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. BiochemBiophysActa1979; 582: 67-78.
12. Heusser J Osswald W. Toxicological properties of diosmin and its action on the isolated venous tissue of the dog. Arch FarmacolToxicol1977; 1: 33-40.
13. Marklund G, Marklund. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem1974; 47:469–474.
14. Sinha AK. Colorimetric assay of catalase. Anal Biochem1972; 47(2):389–394.
15. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hekstra WG. Selenium biochemical role as a component of glutathione peroxidase purification and assay. Science 1973; 179:588–590.
16. OmayeST, Turnbull JD, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cells, tissues and fluids. Methods Enzymol1979; 62:3–11.
17. Desai ID. Vitamin E analysis methods for animal tissues. Methods Enzymol1984; 105:138–147.
18. Stekhoren MA Bonting SL. Transport ATPases: properties and functions. Physiol Rev 1981; 61: 1–76.
19. Hjerten S, Pan H. Purification and characterization of two forms of a low affinity Ca2+-ATPase from erythrocyte membranes. BiochemBiophys Acta1983; 728: 281-288.
20. Ohnishi T, Suzuki T, Suzuki Y, Ozawa K. A comparative study of plasma membrane Mg2+-ATPase activities in normal, regenerating and malignant cells. Biochem Biophys Acta1982; 684: 67-74.
21. King J. The dehydrogenases or oxidoreductase lactate dehydrogenase. In: Practical Clinical Enzymology, Van, D. (Ed.). Nostrand Company Limited, London;1965c. p. 83-93.
22. Slater EC, Borner WD. The effect of flurise on the Succinic oxidase system. Biochem J 1952; 52(2): 185-196.
23. Mehler AH, Kornberg A, Grisolia S, Ochoa S. The enzymatic mechanism of oxidation-reductions between malate or isocitrate and pyruvate. J Biol Chem 1948; 174: 961-977.
24. Reed LJ, Mukherjee BB. α-Ketoglutarate dehydrogenase complex from Escherichia coli. Methods Enzymol1969; 13: 55-61.
25. Brandstrup N, Kirk JE, Bruni C. The hexokinase and phosphoglucoisomerase activities of aortic and pulmonary artery tissue in individuals of various ages. J Gerentol1957; 12(2): 166-171.
26. Horrocks JE, Ward J, King J. A routine method for the determination of phosphogluco isomerase activity in body fluid. J Clin Pathol1963; 16(3): 248-251.
27. King, J (1965b). The phosphohydrolysases-acid and alkaline transaminase, In: Practical Clinical Enzymology, (Eds.) by Van Nostrand Co. Ltd., London. pp. 191-208
28. Gancedo JM, Gancedo C. Fructose 1,6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non-fermenting yeasts. Arch Mikrobiol1971; 76: 132-138.
29. Niebes P. Determination of enzymes and degradation products of glycosaminoglycan metabolism in the serum of healthy and varicose subjects. Clin Chim Acta 1972; 42: 399-408.
30. Wagner WD. A more sensitive assay discriminating galactosamine and glucosamine in mixtures. Anal Biochem1979; 94: 394-397.
31. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959; 234: 1971-1975.
32. Stockert JC, Blázquez-Castro A, Cañete M, Horobin RW, Villanueva A. MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem 2012; 114(8): 785-96.
33. Sivalokanathan S, Vijayababu MR, Balasubramanian MP. Effects of Terminalia arjuna bark extract on apoptosis of human hepatoma cell line HepG2. World J Gastroenterol 2006; 12(7): 1018-24.
34. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis.HormMetab Res 2003; 35(11-12): 685-93.
35. Boots AW, Drent M, Swennen EL, Moonen HJ, Bast A, Haenen GR. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir Med2009; 103(3):364-72.
36. Bhattacharjee R, Sil PC. Protein isolate from the herb, Phyllanthus niruri L. (Euphorbiaceae), plays hepatoprotective role against carbon tetrachloride induced liver damage via its antioxidant properties. Food Chem Toxicol 2007; 45(5): 817-26.
37. Khan F, Khan TJ, Kalamegam G, Pushparaj PN, Chaudhary A, Abuzenadah A, et al. Anti-cancer effects of Ajwa dates (Phoenix dactylifera L.) in diethylnitrosamine induced hepatocellular carcinoma in Wistar rats. BMC Complement Altern Med 2017; 17(1): 418.
38. Sadeeshkumar V, Duraikannu A, Ravichandran S, Fredrick WS, Sivaperumal R, Kodisundaram P.Protective effects of dieckol on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Biomed Pharmacother. 2016; 84: 1810-1819.
39. Li H, Wang P, Gao Y, Zhu X, Liu L, Cohen L, et al.Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin.Oncol Rep 2011; 25 (3): 825-30.
40. Lee YK, Woo HG, Yoon G. Mitochondrial defects-responsive gene signature in liver-cancer progression. BMB Rep 2015; 48 (11): 597-8.
41. Dai Q, Yin Q, Wei L, Zhou Y, Qiao C, Guo Y, et al.Oroxylin A regulates glucose metabolism in response to hypoxia stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells.Mol Carcinog 2016; 55 (8): 1275-89.
42. Aranganathan S, Senthil K, Nalini N. A case control study of glycoprotein status in ovarian carcinoma. Clin Biochem 2005;38(6):535-9.
43. Creppy EE, Lugnier AA, Beck G, Dirheimer G, Petzinger E, Frimmer M. Comparative studies by scanning electron microscopy of the effect of ricin on the cell membrane of hepatoma cells and isolated hepatocytes. Toxicol Eur Res 1981; 3(4): 179-84.